molecules of the month


oral BTK inhibitor

Ph. I candidate in NHL/CLL patients

from Janssen cmp. collection screen and opt.

J. Med. Chem.

Janssen, San Diego, CA

JNJ-64264681 chemical structure oral BTK inhibitor - Janssen, San Diego, CA
4 mins read

Context. JNJ-64264681 (Janssen) is a covalent Bruton’s tyrosine kinase (BTK) inhibitor being developed for hematological malignancies. The first-in-class irreversible BTKi (ibrutinib) was approved in 2013, while many others have been approved or are in clinical development with potentially reduced off-target effects. We recently covered another covalent BTKi, rilzabrutinib, (PRN1008; Sanofi), currently in Ph. III for immune thrombocytopenia. JNJ-64264681 demonstrates nanomolar oral efficacy in both lymphoma and autoimmune models and improved kinase selectivity. It is currently in early clinical development as both a single agent and combination therapy with an aim to reduce adverse effects and patient relapse rates and improve efficacy compared to other BTKi’s on the market. ibrutinib rilzabrutinib Editor Commentary. This is an interesting example of an oral…

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: